专利检索 ap:("The Broad Institute, Inc." OR "Dana-Farber Cancer Institute, Inc." OR "The General Hospital Corporation") AND inv:"SUNDBERG, Thomas" 第 1 页

1.

发明公开
BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF 审中-公开

公开(公告)号：EP3481830A1

公开(公告)日：2019-05-15

申请号：EP17740232.8

申请日：2017-07-05

申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation

发明人： GRAY, Nathanael, S. , LIANG, Yanke , CHOI, Hwan, Geun , SUNDBERG, Thomas , SHAMJI, Alykhan , XAVIER, Ramnik , FISHER, David E. , MUJAHID, Nisma

IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P7/00 , A61P19/00 , A61P21/00 , A61P25/00 , A61P37/00

2.

发明公开
BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF 审中-公开

公开(公告)号：EP4047001A3

公开(公告)日：2022-11-30

申请号：EP21218204.2

申请日：2017-07-05

申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation

发明人： GRAY, Nathanael S. , LIANG, Yanke , CHOI, Hwan Geun , SUNDBERG, Thomas , SHAMJI, Alykhan , XAVIER, Ramnik , FISHER, David E. , MUJAHID, Nisma

IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P7/00 , A61P19/00 , A61P21/00 , A61P25/00 , A61P37/00

摘要： The present disclosure provides compounds of Formula ( I ), ( II ), and ( III ). The provided compounds are able to bind protein kinases ( e . g ., SIK) and may be useful in modulating ( e.g., inhibiting) the activity of a protein kinase ( e.g., SIK, ( e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease ( e . g ., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

3.

发明公开
BICYCLIC UREA KINASE INHIBITORS AND USES THEREOF 审中-公开

公开(公告)号：EP4047001A2

公开(公告)日：2022-08-24

申请号：EP21218204.2

申请日：2017-07-05

申请人： The Broad Institute, Inc. , Dana-Farber Cancer Institute, Inc. , The General Hospital Corporation

发明人： GRAY, Nathanael S. , LIANG, Yanke , CHOI, Hwan Geun , SUNDBERG, Thomas , SHAMJI, Alykhan , XAVIER, Ramnik , FISHER, David E. , MUJAHID, Nisma

IPC分类号： C07D487/04 , A61K31/519 , A61P35/00 , A61P7/00 , A61P19/00 , A61P21/00 , A61P25/00 , A61P37/00

摘要： The present disclosure provides compounds of Formula ( I ), ( II ), and ( III ). The provided compounds are able to bind protein kinases ( e . g ., SIK) and may be useful in modulating ( e.g., inhibiting) the activity of a protein kinase ( e.g., SIK, ( e.g., SIK1, SIK2, or SIK3)) in a subject or cell. The provided compounds may be useful in treating or preventing a disease ( e . g ., proliferative disease, musculoskeletal disease, genetic disease, hematological disease, neurological disease, painful condition, psychiatric disorder, or metabolic disorder) in a subject in need thereof. Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein.

4.

发明公开
USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS 审中-公开
标题翻译：盐诱导激酶（SIK）抑制剂的用途

公开(公告)号：EP3177295A2

公开(公告)日：2017-06-14

申请号：EP15829427.2

申请日：2015-08-08

申请人： Dana Farber Cancer Institute, Inc. , The Broad Institute, Inc. , The General Hospital Corporation d/b/a Massachusetts General Hospital , President and Fellows of Harvard College

发明人： SHAMJI, Alykhan , SUNDBERG, Thomas , GRAY, Nathanael , XAVIER, Ramnik , SCHREIBER, Stuart L. , CHOI, Hwan Geun , LIANG, Yanke

IPC分类号： A61K31/519 , A61K31/5377 , C07D498/02

CPC分类号： A61K31/519 , A61K31/506 , A61K31/5377 , A61K45/06

摘要： The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula (I), imidazolyl SIK inhibitors of Formula (II), and urea and carbamate SIK inhibitors of Formula (III -A) (e.g., urea and carbamate SIK inhibitors of Formula (III)).

摘要翻译： 本公开内容提供了使用盐诱导型激酶（SIK）抑制剂例如式（I）的大环SIK抑制剂，咪唑基SIK（例如咪唑基SIK抑制剂）治疗和/或预防炎性肠病（IBD）和移植物抗宿主病（GVHD）式（II）的抑制剂和式（III-A）的脲和氨基甲酸酯SIK抑制剂（例如式（III）的脲和氨基甲酸酯SIK抑制剂）。

5.

发明公开
USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS 审中-公开

公开(公告)号：EP3536323A1

公开(公告)日：2019-09-11

申请号：EP19164054.9

申请日：2015-08-08

申请人： Dana Farber Cancer Institute, Inc. , The Broad Institute , The General Hospital Corporation d/b/a Massachusetts General Hospital , President and Fellows of Harvard College

发明人： SHAMJI, Alykhan , SUNDBERG, Thomas , GRAY, Nathanael , XAVIER, Ramnik , SCHREIBER, Stuart L. , CHOI, Hwan Geun , LIANG, Yanke

IPC分类号： A61K31/519 , A61P1/00 , A61P37/00

摘要： The present disclosure provides methods of treating and/or preventing inflammatory bowel disease (IBD) and graft-versus-host disease (GVHD) using salt-inducible kinase (SIK) inhibitors, such as macrocyclic SIK inhibitors of Formula ( I ), imidazolyl SIK inhibitors of Formula ( II ), and urea and carbamate SIK inhibitors of Formula ( III-A ) ( e.g ., urea and carbamate SIK inhibitors of Formula ( III )).